Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report.

Reynolds D, Mitteer LM, Sigal W, Boyajian L, McKnight H, Bhatti T, States L, Becker S, Adzick NS, Lord K, De Leon DD

Hormone research in paediatrics14 Jul 2023

PMID37454652 (opens in a new tab)DOI10.1159/000531251 (opens in a new tab)PepBankPUB-37454652
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an adolescent with refractory hyperinsulinemic hypoglycemia and suspected insulinoma, dasiglucagon achieved appropriate glycemic control.

    In plain wordsIn an adolescent with refractory hypoglycemia and suspected insulinoma, dasiglucagon achieved appropriate blood sugar control.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableGlycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient has tolerated the medication and has been able to achieve appropriate glycemic control.
    3 context sentences
    Summary · context
    A 17-year-old, previously healthy male presented with recurrent and severe episodes of hypoglycemia.
    Summary · context
    Diagnostic evaluation was consistent with hyperinsulinemic hypoglycemia, and an insulinoma was suspected.
    Summary · context
    Upon approval from the US Food and Drug Administration and the Institutional Review Board, the patient was treated with dasiglucagon, a novel soluble glucagon analog, under a single-patient Investigational New Drug.
  2. 02HumanCase report or seriesSafety outcome

    The adolescent with suspected insulinoma tolerated dasiglucagon.

    In plain wordsThe adolescent with suspected insulinoma tolerated dasiglucagon.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableTolerability
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient has tolerated the medication and has been able to achieve appropriate glycemic control.
    3 context sentences
    Summary · context
    A 17-year-old, previously healthy male presented with recurrent and severe episodes of hypoglycemia.
    Summary · context
    Diagnostic evaluation was consistent with hyperinsulinemic hypoglycemia, and an insulinoma was suspected.
    Summary · context
    Upon approval from the US Food and Drug Administration and the Institutional Review Board, the patient was treated with dasiglucagon, a novel soluble glucagon analog, under a single-patient Investigational New Drug.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.